**Core tip:** Multisystem smooth muscle dysfunction syndrome (MSMDS) is a genetic disease that is clinically characterized by dysfunction of the smooth muscle throughout the whole body, leading to congenital fixed dilated pupils, patent ductus arteriosus, aortic and cerebrovascular disease, hypotonic bladder, intestinal hypoperistalsis, and pulmonary hypertension. MSMDS is rare in Chinese individuals. It is mostly caused by a p.R179H mutation in the actin alpha 2 gene worldwide. In the present study, we report a heterozygous mutation c.536G\>A, p. R179H in a Chinese infant with MSMDS and describe the clinical characteristics. In addition, we further review the literature regarding MSMDS cases from the 1980s to 2018.

INTRODUCTION
============

Multisystem smooth muscle dysfunction syndrome (MSMDS) is a genetic disease caused mostly by mutation of the actin alpha 2 (*ACTA2*) gene p.R179H. Its clinical manifestation is characterized by fixed dilated pupils, patent ductus arteriosus (PDA), thoracic aortic aneurysm, pulmonary artery hypertension, cerebrovascular disease, white matter lesions, hypotonic bladder, intestinal malrotation, hypoperistalsis and so on. The *ACTA2* gene encodes an isoform of α-actin. Mutations in this gene lead to disruption of smooth muscle cells (SMC)-dependent organs\[[@B1],[@B2]\]. Milewicz et al\[[@B1]\] first reported six patients with a de novo missense mutation in the *ACTA2* gene and MSMDS in 2010. In China, the first case of MSMDS was not reported until 2017 by Zhou et al\[[@B3]\]. Since the *ACTA2* gene was first identified as the pathogenic gene of MSMDS in 2010, only 32 patients have been reported, according to the databases of PubMed, Wanfang, China National Knowledge Infrastructure, and VIP with the key words "multisystem smooth muscle dysfunction syndrome" and ''*ACTA2*" from 1980s to 2018. Three different mutation loci have been reported to cause MSMDS, of which Arg179His is the most common mutation. Other rare mutations are Arg179Cys and Arg179Leu\[[@B2],[@B4]-[@B7]\]. The Arg179His substitution is associated with the neurovascular phenotype, while the Arg179Cys mutation is especially related to brain development\[[@B6]\]. The most severe form is *ACTA2* Arg179His. The discovery of this mutation has been invariably associated with a high risk of infant mortality and poor prognosis\[[@B6]\]. Here, we report one Chinese infant with MSMDS with a heterozygous *ACTA2* Arg179His substitution who presented with patent foramen ovale, congenital nonreactive mydriasis, dyspnea, development delay, and abnormal signals in magnetic resonance imaging (MRI) of the brain. In addition, we further review the literature regarding MSMDS patients from the 1980s to 2018s. The clinical features of all identified MSMDS patients are summarized.

CASE PRESENTATION
=================

Chief complaints
----------------

A girl aged 9.6 months was admitted to Children's Hospital Soochow University in May 2018 due to recurrent cough for more than half a month, which was aggravated by shortness of breath and dyspnea for three days.

History of past illness
-----------------------

She had experienced pneumonia at birth and suffered from growth retardation.

Personal and family history
---------------------------

The child was born by cesarean section at 35 + 2 wk. Her father and mother were healthy. Her twin sister died in April 2018 of lung infection after an operation for "atrial septal defect and ventricular septal defect".

Physical examination
--------------------

She weighed 9 kg, her height was 65 cm, her body mass index was 21.3, and she presented with shortness of breath and dyspnea. Blue-purple plaques could be seen on her right face, buccal mucosa, oral tongue, and palate. Her bilateral pupils were fixed and dilated with a diameter of 5 mm. Crackles and wheezing rales were present in bilateral lungs. A grade II/6 murmur was audible on the left sternal margin. No clubbed digits were found.

Laboratory examinations
-----------------------

Routine blood examination showed a white blood cell count of 8.17 × 10^9^/L, and the C reactive protein concentration was normal. Nasopharyngeal secretion examination revealed positive respiratory syncytial virus and negative sputum culture.

Imaging examinations
--------------------

Chest high-resolution computed tomography revealed inhomogeneous lung transparency, obvious exudative lesions, and marked thickening of lung fissures (Figure [1](#F1){ref-type="fig"}). Cranial magnetic resonance imaging showed abnormal signals in the centrum ovale majus and bilateral periventricular regions (Figure [2](#F2){ref-type="fig"}). Abdominal ultrasonography suggested gallstones (Figure [3](#F3){ref-type="fig"}). Echocardiography only showed patent foramen ovale at the beginning of the disease, but the diameter of the pulmonary artery gradually widened during continuous follow-up (Figure [4](#F4){ref-type="fig"}). Bronchoscopy revealed redness and edema of the bronchial mucous membranes accompanied by phlegm spots and bronchomalacia (Figure [5](#F5){ref-type="fig"}).

![Chest high-resolution computed tomography images. A chest high-resolution computed tomography scan showed inhomogeneous lung transparency and obvious exudative lesions, and some lung fissures were markedly thickened in the lung of the patient.](WJCC-7-4355-g001){#F1}

![Cranial magnetic resonance imaging of the patient. Magnetic resonance imaging showed abnormal signals in the centrum ovale majus and bilateral periventricular regions.](WJCC-7-4355-g002){#F2}

![Abdominal ultrasonography images. Abdominal ultrasonography revealed a strong echo mass of approximately 4 × 6 in size in the gallbladder.](WJCC-7-4355-g003){#F3}

![Echocardiography. Echocardiography showed a widening pulmonary artery.](WJCC-7-4355-g004){#F4}

![Bronchoscopic findings. Bronchoscopy revealed redness and edema of the bronchial mucous membranes. Phlegm spots were observed in the left lung, and bronchomalacia was observed in bilateral lungs.](WJCC-7-4355-g005){#F5}

Gene sequence analysis
----------------------

The patient underwent genetic analysis and the *ACTA2* c.536G\>A (p.R179H) heterozygous mutation was found, but her parents' sample identifications were negative (Figure [6](#F6){ref-type="fig"}).

![Genomic sequence of the patient. Sequencing map of the actin alpha2 (*ACTA2*) gene showed a C-T heterozygous variation at nucleotide 536 in the coding region of the *ACTA2* gene, causing 179 amino acid changes. No genetic mutations were found in her parents.](WJCC-7-4355-g006){#F6}

FINAL DIAGNOSIS
===============

MSMDS.

TREATMENT
=========

Her symptoms improved after oxygen therapy, cefazoxime administration for 3 wk, and antiasthenic and low-dose corticosteroid treatment for 3 wk.

OUTCOME AND FOLLOW-UP
=====================

After being discharged from our hospital, the child was followed monthly in the outpatient clinic. We administered low-dose azithromycin and low-dose corticosteroid anti-inflammatory treatment. We performed regular examinations of respiratory rate, oxygen saturation, and high-resolution computed tomography of the chest to evaluate the pulmonary disease regression/progression, and echocardiography to evaluate the function of the heart. She had pulmonary infection three times, and her latest echocardiographic results suggested pulmonary artery dilatation. She weighed 10 kg, her height was 72 cm, and her body mass index was 19.3. Her overall situation has remained well to date.

DISCUSSION
==========

Tables [1](#T1){ref-type="table"}-[4](#T4){ref-type="table"} summarizes the systemic features of the reported patients with MSMDS worldwide\[[@B8]-[@B16]\]. SMCs are widely distributed in the gastrointestinal tract, urinary tract, respiratory tract, uterus, iris, and other body parts. Their contraction and relaxation are key to the normal operation of blood vessels as well as the digestive system, respiratory system, and urogenital system. MSMDS is mainly caused by p.R179H mutations of the *ACTA2* gene in aortic smooth muscle. This disease is a systemic disorder of smooth muscle function and manifests in a variety of ways, including fixed dilated pupils, PDA, thoracic aortic aneurysm, pulmonary artery hypertension, cerebrovascular disease, white matter lesions, hypotonic bladder, intestinal malrotation, and hypoperistalsis. Other rare symptoms, including pulmonary cystic disease, venous thrombosis, cleft palate, hypothyroidism, and deepened skin folds, need further study to confirm the relationship with this mutation.

###### 

Clinical characteristics of multisystem smooth muscle dysfunction syndrome patients worldwide

  **Characteristic**               **Milewicz et al\[[@B1]\], 2010 *(n* = 6)**   **Munot et al\[[@B2]\], 2012 *(n* = 6)**   **Moller et al\[[@B5]\], 2012 *(n* = 1)**                                                  
  -------------------------------- --------------------------------------------- ------------------------------------------ ------------------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ------ ----
  Gender                           F                                             M                                          M                                           F    F    F    F    F    M    F    M    F      M
  Age (yr)                         11                                            14                                         17                                          11   26   27   3    6    5    2    6    0.25   6
  Vision system                                                                                                                                                                                                        
  Congenital mydriasis             \+                                            \+                                         \+                                          \+   \+   \+   \+   \+   \+   \+   \+   \+     \+
  Retinal vascular tortuosity      \+                                            \+                                                                                                                                    \+
  Cardiovascular system                                                                                                                                                                                                
  PDA                              \+                                            \+                                         \+                                          \+   \+   \+   \+   \+   \+   \+   \+   \+     \+
  ASD                              \-                                            \-                                         \-                                          \-   \-   \-   \-   \-   \-   \-   \-   \-     \-
  PAH                              \-                                            \-                                         \+                                          \+   \+   \-                                   \-
  TAA                              \+                                            \+                                         \+                                          \+   \+   \-                                   \-
  AAD                              \-                                            \-                                         \-                                          \-   \-   \-                                   \+
  PAD                              \+                                            \+                                         \-                                          \+   \-   \-                                   \-
  Nervous system                                                                                                                                                                                                       
  Development delay                \+                                            \-                                         \+                                          \+   \-                                        \-
  Spastic seizures/epilepsy                                                                                                                                                                                            
  Cerebral infarction/hemiplegia   \+                                            \+                                         \-                                          \-   \-   \-   \+   \+   \-   \+   \-   \-     \-
  WM signal changes                \+                                            \+                                         \+                                          \+   \+   \-   \+   \+   \+   \+   \+   \-     \+
  Moyamoya-like changes            \+                                            \+                                         \+                                          \+   \+   \+   \+   \+   \+   \+   \+   \+     \-
  Digestive system                                                                                                                                                                                                     
  Intestinal malrotation           \-                                            \-                                         \+                                          \+   \-   \+                                   
  Intestinal hypoperistalsis       \-                                            \-                                         \+                                          \+   \-   \-                                   
  Gallstones                                                                                                                                                                      \+                                   
  Respiratory system                                                                                                                                                                                                   
  Dyspnea                          \+                                            \+                                         \+                                          \+   \-   \-                                   \+
  RRTI                             \-                                            \-                                         \-                                          \-   \-   \-                                   \-
  Asthma                           \-                                            \-                                         \-                                          \-   \-   \+                                   \-
  Urinary system                                                                                                                                                                                                       
  Hypotonic bladder                \+                                            \+                                         \+                                          \+   \+   \-                                   \+
  Hydronephrosis                                                                                                                                                                                                       
  Hypospadias                                                                                                                                                                                                          
  *ACTA2* mutation                 H                                             H                                          H                                           H    H    H    H    H    L    H    H    H      L
  Prognosis                        D                                                                                                                                                                  D                

+: Present; -: Absent; blank: Unknown; PDA: Patent ductus arteriosus; ASD: Atrial septal defect; PAH: Pulmonary artery hypertension; TAA: Thoracic aortic aneurysm; AAD: Ascending aorta dilatation; PAD: Pulmonary artery dilatation; WM: White matter; RRTI: Recurrent upper respiratory tract infection; H: R179H; C: R179C; L: R179L; D: Death.

###### 

Clinical characteristics of multisystem smooth muscle dysfunction syndrome patients worldwide

  **Characteristic**                                       **Meuwissen et al\[[@B4]\], 2012**   **Al-Mohaissen et al\[[@B8]\], 2012**   **Moosa et al\[[@B9]\], 2013**   **Roulez et al\[[@B10]\], 2014**   **Brodsky et al\[[@B11]\], 2014**        
  ----------------------- -------------------------------- ------------------------------------ --------------------------------------- -------------------------------- ---------------------------------- ----------------------------------- ---- ----
  *n*                                                      1                                    1                                       1                                3                                  1                                        
  Gender                                                   F                                    F                                       F                                F                                  F                                   F    M
  Age (yr)                                                 3                                    17                                      7                                19                                 14                                  16   9
  Vision system           Congenital mydriasis             \+                                   \+                                      \+                               \+                                 \+                                  \+   \+
                          Retinal vascular tortuosity      \+                                   \+                                                                       \+                                 \+                                  \+   \+
  Cardiovascular system   PDA                              \+                                   \+                                      \+                               \+                                 \+                                  \+   \+
                          ASD                              \-                                   \-                                      \-                               \-                                 \-                                  \-   \+
                          PAH                              \+                                   \-                                      \-                               \+                                 \-                                  \-   \-
                          TAA                              \-                                   \-                                      \-                               \-                                 \+                                  \-   \-
                          AAD                              \-                                   \+                                      \-                               \-                                 \-                                  \+   \+
                          PAD                              \-                                   \-                                      \-                               \-                                 \-                                  \-   \-
  Nervous system          Development delay                \-                                   \-                                      \+                               \+                                 \+                                  \-   
                          Spastic seizures/epilepsy                                                                                     \+                                                                                                           
                          Cerebral infarction/hemiplegia   \-                                   \-                                      \-                               \-                                 \-                                  \-   \-
                          WM signal changes                \+                                   \-                                      \+                               \-                                 \+                                  \+   \-
                          Moyamoya-like changes            \-                                   \-                                      \+                               \+                                 \+                                  \-   \-
  Digestive system        Intestinal malrotation           \+                                                                           \-                               \-                                                                          
                          Intestinal hypoperistalsis       \-                                                                           \+                               \+                                                                          
                          Gallstones                                                                                                                                     \+                                                                          
  Respiratory system      Dyspnea                          \+                                   \-                                      \+                               \+                                 \-                                  \+   \-
                          RRTI                             \+                                   \-                                      \-                               \+                                 \-                                  \+   \-
                          Asthma                           \-                                   \-                                      \-                               \+                                 \-                                  \+   \-
  Urinary system          Hypotonic bladder                \+                                   \-                                      \-                               \+                                 \-                                  \-   \-
                          Hydronephrosis                   \+                                                                                                                                                                                        \+
                          Hypospadias                                                                                                                                                                                                                \+
  *ACTA2* mutation                                         C                                    H                                       H                                H                                  H                                   H    H
  Prognosis                                                D                                                                                                                                                                                         

+: Present; -: Absent; blank: Unknown; PDA: Patent ductus arteriosus; ASD: Atrial septal defect; PAH: Pulmonary artery hypertension; TAA: Thoracic aortic aneurysm; AAD: Ascending aorta dilatation; PAD: Pulmonary artery dilatation; WM: White matter; RRTI: Recurrent upper respiratory tract infection; H: R179H; C: R179C; L: R179L; D: Death.

###### 

Clinical characteristics of multisystem smooth muscle dysfunction syndrome patients worldwide

  **Characteristic**                                       **Amans et al\[[@B12]\], 2014**   **Yetman et al\[[@B13]\], 2015**   **Richer et al\[[@B14]\], 2012**   **De et al\[[@B6]\], 2016**   **Moreno et al\[[@B7]\], 2016**              
  ----------------------- -------------------------------- --------------------------------- ---------------------------------- ---------------------------------- ----------------------------- --------------------------------- ----- ---- -----
  *n*                                                      1                                 3                                  1                                  2                             1                                            
  Gender                                                   F                                 F                                  F                                  F                             M                                 F     M    F
  Age(yr)                                                  3                                 15                                 0.9                                31                            2                                 0.2        0.8
  Vision system           Congenital mydriasis             \+                                \+                                 \+                                 \+                            \+                                \+    \+   \+
                          Retinal vascular tortuosity                                        \+                                 \+                                 \+                                                                         
  Cardiovascular system   PDA                              \+                                \+                                 \+                                 \+                            \+                                \+    \+   \+
                          ASD                              \-                                \+                                 \+                                 \+                            \-                                \-    \+   \+
                          PAH                              \-                                \+                                 \+                                 \+                            \+                                \+    \-   \-
                          TAA                              \-                                \+                                 \-                                 \+                            \-                                \-    \-   \-
                          AAD                              \-                                \+                                 \+                                 \+                            \+                                \-    \+   \-
                          PAD                              \-                                \+                                 \+                                 \+                            \+                                \-    \+   \-
  Nervous system          Development delay                                                                                                                                                      \+                                           
                          Spastic seizures/epilepsy                                          \+                                 \-                                 \+                                                                         
                          Cerebral infarction/hemiplegia   \-                                \-                                 \-                                 \-                            \-                                \-    \-   \-
                          WM signal changes                \-                                \+                                 \+                                 \+                            \+                                \-    \+   \-
                          Moyamoya-like changes            \+                                \+                                 \-                                 \-                            \+                                \+    \+   \+
  Digestive system        Intestinal malrotation                                             \+                                 \+                                 \-                                                                         \+
                          Intestinal hypoperistalsis                                         \-                                 \-                                 \+                                                                         \+
                          Gallstones                                                                                                                                                                                                          
  Respiratory system      Dyspnea                          \-                                \-                                 \+                                 \-                            \+                                      \+   
                          RRTI                             \-                                \-                                 \-                                 \-                            \-                                      \-   
                          Asthma                           \-                                \-                                 \-                                 \-                            \-                                      \-   
  Urinary system          Hypotonic bladder                \+                                \+                                 \-                                 \+                            \+                                \-    \+   \+
                          Hydronephrosis                                                                                                                                                         \-                                \+    \+   \+
                          Hypospadias                                                                                                                                                            \+                                \+    \+   \+
  *ACTA2* mutation                                         H                                 H                                  H                                  H                             H                                 C     C    C
  Prognosis                                                                                                                     D                                                                                                  D          

+: Present; -: Absent; blank: Unknown; PDA: Patent ductus arteriosus; ASD: Atrial septal defect; PAH: Pulmonary artery hypertension; TAA: Thoracic aortic aneurysm; AAD: Ascending aorta dilatation; PAD: Pulmonary artery dilatation; WM: White matter; RRTI: Recurrent upper respiratory tract infection; H: R179H; C: R179C; L: R179L; D: Death.

###### 

Clinical characteristics of multisystem smooth muscle dysfunction syndrome patients worldwide

  **Characteristic**                                       **Prabhu et al\[[@B15]\], 2017**   **Logeswaran et al\[[@B16]\], 2017**   **Zhou et al\[[@B3]\], 2017**   **Our patient**   **Observed Cases (*n*)**   **Positive cases, *n* (%)**   
  ----------------------- -------------------------------- ---------------------------------- -------------------------------------- ------------------------------- ----------------- -------------------------- ----------------------------- -----------
  *n*                                                      1                                  2                                      1                               1                                                                          
  Gender                                                   F                                  M                                      F                               F                 F                          33                            
  Age (yr)                                                 0.4                                3 (d)                                  26                              2                 0.8                                                      
  Vision system           Congenital mydriasis             \+                                 \+                                     \+                              \+                \+                         33                            33 (100)
                          Retinal vascular tortuosity                                         \+                                     \+                              \+                \-                         16                            15 (93.8)
  Cardiovascular system   PDA                              \+                                 \+                                     \+                              \+                \-                         33                            32 (97.0)
                          ASD                              \-                                 \-                                     \-                              \-                \-                         33                            6 (18.2)
                          PAH                              \+                                 \-                                     \+                              \+                \-                         27                            13 (48.1)
                          TAA                              \-                                 \-                                     \+                              \-                \-                         27                            9 (33.3)
                          AAD                              \-                                 \-                                     \-                              \-                \-                         27                            9 (33.3)
                          PAD                              \+                                 \-                                     \+                              \-                \+                         27                            11 (40.7)
  Nervous system          Development delay                \+                                                                                                        \+                \+                         16                            10 (62.5)
                          Spastic seizures/epilepsy                                                                                                                                    \-                         5                             3 (60.0)
                          Cerebral infarction/hemiplegia                                      \-                                     \-                              \-                \-                         32                            5 (15.6)
                          WM signal changes                                                   \+                                     \+                              \+                \-                         32                            23 (71.9)
                          Moyamoya-like changes                                               \-                                     \+                              \+                \-                         32                            23 (71.9)
  Digestive system        Intestinal malrotation           \-                                 \-                                     \-                                                \-                         17                            7 (41.2)
                          Intestinal hypoperistalsis       \-                                 \-                                     \-                                                \-                         17                            6 (35.3)
                          Gallstones                                                          \-                                     \-                                                \+                         5                             3 (60.0)
  Respiratory system      Dyspnea                          \+                                                                                                                          \+                         23                            15 (65.2)
                          RRTI                             \+                                                                                                                          \+                         23                            5 (21.7)
                          Asthma                           \-                                                                                                                          \-                         23                            3 (13.0)
  Urinary system          Hypotonic bladder                                                   \-                                     \-                                                                           24                            14 (58.3)
                          Hydronephrosis                                                      \-                                     \-                                                \-                         9                             5 (55.6)
                          Hypospadias                                                         \-                                     \-                                                \-                         8                             5 (62.5)
  *ACTA2* mutation                                         H                                  H                                      H                               H                 H                                                        
  Prognosis                                                                                                                                                                                                                                     

+: Present; -: Absent; blank: Unknown; PDA: Patent ductus arteriosus; ASD: Atrial septal defect; PAH: Pulmonary artery hypertension; TAA: Thoracic aortic aneurysm; AAD: Ascending aorta dilatation; PAD: Pulmonary artery dilatation; WM: White matter; RRTI: Recurrent upper respiratory tract infection; H: R179H; C: R179C; L: R179L; D: Death.

In 2010, Milewicz et al\[[@B1]\] first reported a case of MSMDS associated with the p.R179H mutation of the *ACTA2* gene. This mutation caused systemic smooth muscle dysfunction, leading to aortic and cerebrovascular diseases, fixed dilated pupils, hypotonic bladder, intestinal malrotation, and pulmonary artery hypertension. In 2017, Zhou et al\[[@B3]\] reported the first case of MSMDS in China. Our case is the second case of MSMDS diagnosed by genetic testing in China. Similar to the reported cases, our patient had congenital mydriasis accompanied by loss of direct light reflex. Iris tissue dissociation was considered an early manifestation of these pupil symptoms\[[@B5]\]. Fundus examination showed no retinal vascular tortuosity in our patient. Moller e*t al*\[[@B5]\] reported the ophthalmic characteristics of three patients with MSMDS in detail. They believed that the retinal vascular tortuosity was due to the lack of elastic lamina in the retinal artery wall, and SMC proliferation resulted in vascular obstruction. Furthermore, the incidence of retinal vascular tortuosity tended to increase with age, which may be related to changes in the vascular wall and the loss of contractility. In cardiovascular diseases, our patient had patent foramen ovale and pulmonary artery dilatation without PDA or pulmonary hypertension, which is different from the reported cases. PDA was present in all reported cases. The ductus arteriosus, similar to the muscular artery, is a duct between the aorta and the pulmonary artery. SMCs play a major role in catheter closure, and their dysfunction leads to the persistence of ductus arteriosus. It has been reported that pulmonary hypertension may be due to the combined action of large PDA and pulmonary parenchymal diseases and that the repair of PDA is essential for the recovery of pulmonary parenchymal diseases\[[@B15]\]. In a long-term follow-up study of three MSMDS patients by Yetman et al\[[@B13]\], they found that the aorta dilated progressively with age, which may be related to the change in α protein structure caused by *ACTA2* mutation leading to the decrease in aortic contractility. However, the role of drug therapy in preventing these cardiovascular lesions is still unknown. With regard to cerebrovascular diseases, our patient received cranial MRI, which showed abnormal signals in the centrum ovale majus and bilateral periventricular regions. As reported, MSMDS mostly began as a pulmonary disease. Our patient had a history of \"neonatal pneumonia\" at birth. When she was 9 mo old, she suffered from shortness of breath, wheezing, and dyspnea and needed long-term oxygen therapy. Roulez et al\[[@B10]\] holds that decreased SMC function of pulmonary alveoles leads to tachypnea at birth, pulmonary hypertension, asthma, bronchiectasis, and emphysema. However, the relationship between the *ACTA2* gene causing MSMDS and lung pathology has not been well elucidated. Prabhu et al\[[@B15]\] believe that pulmonary vascular changes may be caused by pulmonary hypertension secondary to PDA or by elevated pulmonary pressure caused by structural disorders of abnormal alveolar growth. However, in the case of the absence of intimal hyperplasia, intimal hypertrophy of small muscle arteries may be caused by the hypercontraction of arterial smooth muscle. Our patient had skin and mucosal symptoms, which manifested as cyan-purple plaques on her right face, buccal mucosa, oral tongue, and palate. Richer et al\[[@B14]\] first reported a case of skin abnormalities in which wrinkles of ankles, knees, buttocks, and elbows were markedly deepened. This may be related to the dysfunction of myofibroblasts expressing *ACTA2* in the skin.

Tables [1](#T1){ref-type="table"}-[4](#T4){ref-type="table"} summarizes the systemic features of the reported patients with MSMDS worldwide. Among the MSMDS patients, the youngest was a neonate, and the oldest was 31 years old. Twenty-three (71.9%) were female, and nine (28.1%) were male. Except for cardiovascular and cerebrovascular diseases, these patients also experienced dysfunction of other SMC-dependent organs, including depressed systolic performance of the bladder and gastrointestinal tract, resulting in hypotonic bladder, hydronephrosis, hypospadias, intestinal malrotation, hypoperistalsis, and gallstones. As shown in Tables [1](#T1){ref-type="table"}-[4](#T4){ref-type="table"}, all patients tested positive for the *ACTA2* gene mutation. The R179H variant was the most common mutation type (81.25%), followed by R179C (12.5%) and R179L (6.25%). This mutation has always been reported to be sporadic, since few patients can survive to reproductive age, and none of the parents who had undergone genetic testing were identified as carriers. By the time of submission, five deaths had been reported in all cases. Our patient was given oxygen therapy and low-dose corticosteroid treatment after discharge. She suffered from pulmonary infection three times, and her latest echocardiographic results suggested pulmonary artery dilatation without pulmonary hypertension.

*ACTA2*, located in the long arm of chromosome 10-10q23.31, is composed of nine exons and codes for actin alpha 2, a major contractile protein in vascular smooth muscle cells. *ACTA2* is one of six actin subclasses in mammals, mainly distributed in muscle cells and is the main component of contractors. By the interaction of the contractile element α actin (*ACTA2* coding) and β myosin heavy chain (MYH11 coding), SMCs can achieve contraction to regulate blood pressure and blood flow. Therefore, there are many overlapping clinical manifestations of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) caused by the mutation of *MYH11* and MSMDS caused by the mutation of *ACTA2*. Yetman et al\[[@B17]\] reported a case of MMIHS with congenital mydriasis, PDA, pulmonary hypertension, aortic dilatation, intestinal malrotation, and hypoperistalsis but no cerebrovascular abnormalities. Therefore, for children with clinical characteristics such as congenital mydriasis and PDA, genetic testing should be carried out as soon as possible. At the same time, eye fundus examination, echocardiography, and cranial MIR should also be performed to observe multisystem lesions.

CONCLUSION
==========

In conclusion, MSMDS is a rare genetic variant disease. According to the literature, the hotspot variant is the heterozygous mutation of the *ACTA2* gene c.536C\>T (p.R179H). Early genetic testing is essential for the optimal management of suspected clinical cases. In addition to early detection of hotspot variation in these patients, clinicians need to examine and evaluate the patients' cerebrovascular, cardiovascular, and pulmonary complications to make early diagnosis and treatment.
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